Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor

Drug Metabolism and Disposition

Volumn 43, Issue 6, 2015, Pages 864-869

  Choo, Edna F ^a   Woolsey, Sarah ^a   Dement, Kevin ^a   Ly, Justin ^a   Messick, Kirsten ^a   Qin, Ann ^a   Takahashi, Ryan ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBIMETINIB; CYTOCHROME P450 3A4; ITRACONAZOLE; RIFAMPICIN; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYP3A7 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; GDC-0973; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTESTINE; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; HALF LIFE TIME; INTESTINE MUCOSA; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; AZETIDINES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL MUCOSA; MAP KINASE KINASE 1; METABOLIC CLEARANCE RATE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES, LIVER; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS;

EID: 84940377250     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.063743     Document Type: Article

References (29)

1. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
2. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
4. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York.
5. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
6. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287.
7. Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, and Scheer N (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518-528.
8. Hill JR (2004) In vitro drug metabolism using liver microsomes. Curr Protoc Pharmacol 23:7.8: 7.8.1-7.8.11.
9. Kwara A, Cao L, Yang H, Poethke P, Kurpewski J, Tashima KT, Mahjoub BD, Court MH, and Peloquin CA (2014) Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy 34:265-271.
10. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
11. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, and Thomas L, et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876.
12. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
13. Mitsui T, Nemoto T, Miyake T, Nagao S, Ogawa K, Kato M, Ishigai M, and Yamada H (2014) A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes. Drug Metab Dispos 42:1540-1547.
14. Musib L, Choo E, Deng Y, Eppler S, Rooney I, Chan IT, and Dresser MJ (2013) Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm 10:4046-4054.
15. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
16. Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93-107.
17. Rowland A, Miners JO, and Mackenzie PI (2013) The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121-1132.
18. Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, and Wolf CR (2012) Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82:1022-1029.
19. Scheer N, Ross J, Kapelyukh Y, Rode A, and Wolf CR (2010) In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos 38:1046-1053.
20. Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N, and Wolf CR (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228-3239.
21. Shen DD, Kunze KL, and Thummel KE (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
22. Tseng E, Walsky RL, Luzietti RA Jr, Harris JJ, Kosa RE, Goosen TC, Zientek MA, and Obach RS (2014) Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 42:1163-1173.
23. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, and Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592.
24. van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, and Schinkel AH (2009a) Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37: 2305-2313.
25. van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, and Schinkel AH (2009b) Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 23:224-231.
26. Van-Waterschoot RA, van-Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, and Schinkel AH (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-1036.
27. Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, and Goosen TC, et al. (2012) Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686-1697.
28. Wilkinson GR and Shand DG (1975) Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
29. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.